Combination of serum RASSF1A methylation and AFP is a promising non-invasive biomarker for HCC patient with chronic HBV infection

Table 1 The baseline clinical data of 584 subjects

Characteristics	HCC (n = 190)	LC (n = 114)	CHB (n = 120)	Health (n = 160)
Age (y)	52.32 ± 18.63	54.65 ± 15.39	54.65 ± 15.33	52.12 ± 16.76
Male	136 (71.58)	76 (66.67)	84 (70.00)	110 (68.75)
ALT (U/L)	62.82 ± 46.27	71.19 ± 32.40	90.81 ± 60.23	24.62 ± 16.28
ALB (g/L)	33.39 ± 14.57	30.18 ± 11.95	38.13 ± 8.26	40.13 ± 4.67
TBIL (μmol/L)	26.54 ± 19.83	76.49 ± 42.35	50.28 ± 46.03	9.81 ± 6.73
PLT (×10⁹/μL)	15.65 ± 13.07	11.36 ± 9.81	16.85 ± 13.49	19.04 ± 10.27
HBeAg (+)	96 (50.52)	60 (52.63)	68 (56.67)	0 (0)
HBV DNA (log₁₀ copies/mL)	5.93 ± 1.86	5.78 ± 1.29	5.87 ± 1.13	0
AFP (≥20 ng/L)	118 (62.11)	62 (54.39)	32 (26.67)	0 (0)

There were significant differences in the levels of ALT, ALB, TBIL, PLT and AFP in the HCC, LC and CHB groups (P < 0.05). All data are presented as mean ± standard deviation or n (%)
HCC hepatocellular carcinoma, LC liver cirrhosis, CHB chronic hepatitis B; ALT alanine aminotransferase, ALB albumin, TBIL total bilirubin, PLT blood platelet, HBeAg HBV e-antigen, AFP α-fetoprotein

ISSN: 1746-1596